Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.

Science (New York, N.Y.) - 19 Feb 2021

Starr Tyler N, Greaney Allison J, Addetia Amin, Hannon William W, Choudhary Manish C, Dingens Adam S, Li Jonathan Z, Bloom Jesse D

Abstract excerpt

Antibodies are a potential therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but the risk of the virus evolving to escape them remains unclear. Here we map how all mutations to the receptor binding domain (RBD) of SARS-CoV-2 affect binding by the antibodies in the REGN-COV2 cocktail and the antibody LY-CoV016. These complete maps uncover a single amino acid mutation that fully escapes the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Viral

Share to Drug Combinations

Share to Immunization, Passive

Share to Protein Domains

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 33495308
DOI: 10.1126/science.abf9302
PMCID: PMC7963219

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.PMID 33495308Read ↗

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19Semantic proximity Read ↗

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognitionSemantic proximity Read ↗

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody RecognitionSemantic proximity Read ↗

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016Semantic proximity Read ↗

Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escapeSemantic proximity Read ↗

Comprehensive Mapping of Binding Hot Spots of SARS-CoV-2 RBD-specific Neutralizing Antibodies for Tracking Immune Escape VariantsSemantic proximity Read ↗

Structural and mutational analyses define distinct molecular routes to broad SARS-CoV-2 receptor-binding domain recognitionSemantic proximity Read ↗

Long-term passaging of replication competent pseudo-typed SARS-CoV-2 reveals the antiviral breadth of monoclonal and bispecific antibody cocktailsSemantic proximity Read ↗

Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.Semantic proximity Read ↗

Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance.Semantic proximity Read ↗

Evaluating SARS-CoV-2 Antibody Resilience via Prediction and Design of Escape Viral VariantsSemantic proximity Read ↗

ESC - a comprehensive resource for SARS-CoV-2 immune escape variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.